Home » Newsletters » BioWorld Science

BioWorld Science

June 19, 2001

View Archived Issues

Candidate mucin production inhibitor presented at ATS 2001

Long-term efficacy and safety data for adalimumab discussed at EULAR 2001

Third phase II trial of LDP-341 begins

Pharming's rhC1 inhibitor granted orphan drug designation from EMEA

InterMune licenses Infergen from Amgen

Anakinra can arrest joint destruction in active rheumatoid arthritis

MIF antagonists and their potential therapeutic application patented by PIMR researchers

Worldwide clinical development program for Generx to be launched

Kaken presents new compounds acting as VLA-4 antagonists

New MMP and TNF-alpha production inhibitors designed by Ajinomoto scientists

Succinic acid derivatives useful for potentiating activity of beta-lactam antibiotics

Naturally produced antiproliferative compounds discovered by CNRS team

Pyrazolone-based kinase inhibitors reported in recent patent by Cephalon

Exploratory trial of IC-351 in female sexual arousal disorder shows no conclusive treatment effect

Milkhaus expands clinical testing of BPH agent

PEG sTNF-RI produces significant improvement in signs, symptoms and HRQOL in RA patients

ImClone reaches second milestone in phase III evaluation of BEC2

Metvix PDT receives first approval in Sweden

Recombinant urate oxidase now available for acute tumor lysis syndrome

Cardioprotective properties demonstrated for LU-135252 in infarcted SHSRP

Novartis seeks E.U. approval of Elidel atopic dermatitis treatment

Receptor subtype-selective muscarinic agonist compares favorably with pilocarpine in primates

Solvay commences Canadian study of Teveten in combination with home blood pressure monitoring

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...